… neuroprotective intervention that reduces the incidence of cerebral palsy (CP) at two years of
age. Clinical evidence of the neuroprotective … the evidence for the neuroprotective effects of …

… neuroprotection in animal models. ► We discuss clinical trials of therapeutic approaches to
neuroprotection. … not be a suitable neuroprotective agent when administered antenatally in a …

… the pathophysiology, current clinical recommendations, and latest research on strategies
to mitigate the impact of or prevent perinatal brain injury (“perinatal neuroprotection”). …

… review discusses the benefits of antenatal MgSO 4 administration for fetal neuroprotection. …
of fetal/infant death or cerebral palsy in the analysis of the 4 trials with fetal neuroprotective …

… available clinical guidelines for the use of magnesium sulfate for fetal neuroprotection and
… included the national and the international clinical practice guidelines. We included seven …

… Using clinically relevant concentrations and doses of … neuroprotection, angiogenesis, and
hemodynamic factors and in measuring, in human fetuses, the impact of a 4‐g neuroprotective …

… clinically used and novel fetal neuroprotective … evidence for the synaptic origins of fetal
neurological disorders and details the use of several clinical and experimental neuroprotective …

A growing body of evidence implies that maternal inflammation during pregnancy is
associated with increased risk of neurodevelopmental disorders in the offspring. The …

… for neuroprotective strategies. New animal models have led to the elucidation of biochemical
events involved in neurodegeneration and neuroprotection. Furthermore, clinical trials of …

… This is, for example, the case of the 19-norprogestatif Nestorone (segesterone acetate), which
is not converted to a GABA A receptor-active metabolite and exerts its neuroprotective and …